175 Galaxy Blvd., Suite 105 Toronto, Ontario M9W 0C9 Tel: 1-844-363-4357 Fax: 647-943-2804 Web: www.lifelabsgenetics.comR. F. Carter, PhD, FCCMG Lab Director

Result Fetal Sex Fetal Fraction

Patient Name:Date of Birth: Estimated Due Date: Maternal Age at EDD: Gestational Age: Maternal Weight: Health Card #: Order ID: Sample ID:Accessioning ID:

ABOUT THIS SCREEN Panorama™ is a screening test, not diagnostic. It evaluates genetic information in the maternal blood, which is a mixture of maternal and placental DNA, to determine the chance for specific chromosome abnormalities. The test does NOT tell with certainty if a fetus is affected, and only tests for the conditions ordered by the healthcare provider. A low risk result does not guarantee an unaffected fetus.

IF THE ORDERING PROVIDER HAS QUESTIONS OR WISHES TO DISCUSS THE RESULTS, PLEASE CONTACT US AT 1-844-363-4357. Ask for the NIPT genetic counsellor on call. For more information, please visit www.lifelabsgenetics.com. LifeLabs Genetics is accredited by the Institute for Quality Management in Healthcare (IQMH) and College of American Pathologists (CAP) and is licensed by the Ontario Ministry of Health and Long-Term Care to operate as a clinical genetic laboratory: MOHLTC license 5806.

Ordering Physician:Genetic Counsellor: Additional Reports:

Test Requested:

Report Date: Samples Collected: Samples Received:

PATIENT INFORMATION PROVIDER INFORMATION

APPROVED BY R.F. Carter, PhD, FCCMG (Laboratory Director)

Condition

>99% (CI 99.1-100)

>99% (CI 87.2-100)

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1/10,000

>99% (CI 99.1-100)95.5% (CI 77.2-99.9)

12 Weeks / 4 Days

>99% (CI 99.1-100)

Trisomy 21

Trisomy 2198.2% (CI 90.4-99.9)

Condition Tested

70 kg2018-02-06

>99% (CI 98.6-99.9)

1/20,000

1/5,000

1. Nicolaides KH et al. Prenat Diagn. 2013 June;33(6):575-92. Pergament E et al. Obstet Gynecol. 2014 Aug;124(2 Pt 1):210-83. Ryan A et al. Fetal Diagn Ther. 2016;40(3):219-2234. Dar P et al. Am J Obstet Gynecol. 2014 Nov;211(5):527.e1-527.e175. Nicolaides KH et al. Fetal Diagn Ther. 2014;35(3):212-7.6. Curnow KJ et al. Am J Obstet Gynecol. 2015 Jan;212(1):79.e1-97. Wapner RJ et al. Am J Obstst Gynecol. 2015 Mar;212(3):332.e1-98. Martin et al. Clin Genetics. 2017 Jul 119. Norvez A et al. The European Human Genetics Conference, ESHG.Copenhagen, Denmark. May 27-30, 2017.

1,2,3,4

>99.9% (CI 99.4-100)

<1/10,000

Male

Sensitivity (95% CI)

2-5%***

91%

>99% (CI 66.4-100)

>99.99%

>99.9% (CI 99.5-100)

90.0% (CI 55.5-99.7)

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3

Not Requested

TESTING METHODOLOGY: DNA isolated from the maternal blood, which contains placental DNA, isamplified at specific loci using a targeted PCR assay, and sequenced using a high-throughput sequencer.Sequencing data is analyzed using Natera's proprietary algorithm to determine the fetal copy number forchromosomes 13, 18, 21, X, and Y, thereby identifying whole chromosome abnormalities at theselocations, and if ordered, the microdeletion panel will identify microdeletions at the specified loci only. If asample fails to meet the quality threshold, no result will be reported for the specified chromosome(s). Thetest requires sufficient fetal fraction of at least 2.8% to produce a result. Fetal fraction refers to thepercentage of fetal (placental) DNA in the maternal plasma compared to the amount of maternal DNA.Fetal fraction is determined using a proprietary algorithm incorporating data from single nucleotidepolymorphism-based next-generation sequencing. Estimates of fetal fraction may differ when measured bydifferent laboratories and/or methodologies.

Angelman syndrome

Angelman syndrome

>99.99%*

DISCLAIMERS: This test has been validated on women with a singleton, twin or egg donor pregnancy of atleast nine weeks gestation. A result will not be available for higher order multiples and multiple gestationpregnancies with an egg donor or surrogate, or bone marrow transplant recipients. Complete test panel isnot available for twin gestations and pregnancies achieved with an egg donor or surrogate. For twinpregnancies with a fetal fraction value below the threshold for analysis, a sum of the fetal fractions for bothtwins will be reported. Findings of unknown significance will not be reported. As this assay is a screeningtest and not diagnostic, false positive and false negatives can occur. High risk test results need diagnosticconfirmation by alternative testing methods, such as chorionic villus sampling (CVS) or amniocentesis. Lowrisk results do not fully exclude the diagnosis of any of the syndromes nor do they exclude the possibility ofother chromosomal abnormalities or birth defects, which are not part of this test. Potential sources ofinaccurate results include, but are not limited to, mosaicism, low fetal fraction, limitations of currentdiagnostic techniques, or misidentification of samples. This test will not identify all deletions associatedwith each microdeletion syndrome. This test has been validated on full region deletions only and may beunable to detect smaller deletions. Microdeletion risk score is dependent upon fetal fraction, as deletionson the maternally inherited copy are difficult to identify at lower fetal fractions. Test results should alwaysbe interpreted by a clinician in the context of the clinical and familial data with the availability of geneticcounselling when appropriate. The Panorama prenatal test was developed by Natera, Inc., 201 IndustrialRoad Suite 410, San Carlos, CA 94070., a laboratory certified under the Clinical Laboratory ImprovementAmendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug administration(FDA).

9/10

5,6

2018-08-09

Result

2/1,000

Maternal Blood

Specificity(95% CI)

Low Risk

5%

DR. M. GOODBIRTH

Low Risk

Positive Predictive Value

BIR13002

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

>99.99%

-

XXX, XXY, XYY

Low Risk

>99.99%*

10%**

Low Risk

1/12,000

MICRODELETIONS

93%

>99.99%*

<1/10,000

JANE DOE

1

2018-CD1234567

>99.99%

89%

5/10,000

Triploidy/Vanishing Twin

Triploidy/Vanishing Twin

99.98-99.99%***

Negative Predictive Value

Risk Before Test

4

1/6,300

50%

Risk After Test

Female

1. Excludes cases with evidence of fetal and/or placental mosaicism. 2. Based on maternal age, gestational age, and/or general population, as applicable. References available upon request. 3. Risk after test for aneuploidy incorporates results from thePanorama algorithm and data from a published study of 17,885 women(4) and are reported as PPV (high risk) and NPV (low risk). Maternal age is utilized in this calculation*. 4. Risk after test for microdeletion(s) incorporates results from the Panoramaalgorithm and data from published studies(8) and are reported as PPV (high risk) and NPV (low risk). Risk for microdeletions is independent of maternal age. Fetal fraction is utilized in this calculation*.*Risk After Test may not reflect the actual PPV for this patient, as additional risk factors, including but not limited to: results of other screening, ultrasound findings, personal/family history, are not included in the risk assessment.

>99% (CI 97.8-99.9)

1980-02-12

FINAL REPORT SUMMARY

1,2,3,4

1,2,3,4

1,2,3,4

4/1,000

20%**

>99% (CI 85.8-100)

* Ongoing clinical follow-up is performed to ensure the NPV does not fall below thequoted value but follow up is not obtained for all low risk calls.** PPV for 22q11.2 deletion syndrome and Angelman syndrome in published studieswas 20% and 10% respectively when no ultrasound anomalies were seen and was upto 100% when ultrasound anomalies were seen prior to testing.*** Dependent upon fetal fraction. For 22q11.2 deletion syndrome, only the paternalallele is evaluated at FF <= 6.5%. For 1p36 deletion syndrome and Cri-du-chatsyndrome, only the paternal allele is evaluated at FF < 7%. For Angelman syndrome,no risk assessment is reported at FF < 7%.Test specifications above are applicable to singleton and monozygotic twin pregnanciesonly. For additional information, please visit: www.natera.com/panorama-test/test-specs

>99% (CI 2.5-100) 7-17%***

Risk Before Test

Condition Tested

1p36 deletion syndrome

1p36 deletion syndrome

______________________________________________________________________________________

______________________________________________________________________________________

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

______________________________________________________________________________________

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<1/10,000

38

>99.9% (CI 99.4-100)

The Panorama risk score reflects analysis of DNA from the placenta. The placental DNA may not accurately reflect the status of the fetus; therefore, noirreversible decisions should be made based upon the results of this screening test alone.

Prader-Willi syndrome

Prader-Willi syndrome

2

1/2,900

93.8% (CI 69.8-99.8)

>99% (CI 99.8-100)

4

Risk Unchanged

Panorama Prenatal Test

2018-01-30

4/1,000

1

94.7% (CI 74.0-99.9)

Monosomy X

Monosomy X

7,8

7,8

7,8

7,8

5.30%

1/13,800

>99% (CI 99.5-100)

>99% (CI 99.1-100)

Low Risk

Result

2

Low Risk

>99% (CI 99.7-100)

Low Risk

>99.99%*

M13002

HIGH RISK for Trisomy 21

RESULT DETAILS

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cri-du-chat syndrome

Cri-du-chat syndrome

>99% (CI 99.7-100)

Microdeletion Extended Panel

>99% (CI 99.7-100)

1/27,0001/12,000

This is a screening test only. Genetic counselling and diagnostic testing should be offered to further evaluate these findings.

Trisomy 13

Trisomy 13

Trisomy 18

Trisomy 18

1/2,000

38%

5.6%

7,8,9

>99.9% (CI 99.5-100)

______________________________________________________________________________________

Low Risk

>99.99%*

HIGH RISK

-

22q11.2 deletion syndrome

22q11.2 deletion syndrome

-

Risk After Test

-

99.97-99.99%***

2018-01-29